Loading
A phase 1/2 trial of Pembrolizumab and Cemiplimab in head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma, run by Rakuten Medical, Inc., active and no longer recruiting.
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04305795 by Rakuten Medical, Inc., with 23 participants enrolled, started 2020-12-21 and due to reach its primary completion in 2026-06. Interventions recorded: 200 mg Pembrolizumab, 350 mg Cemiplimab and ASP-1929 PIT.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rakuten Medical, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Advanced cutaneous squamous cell carcinoma, Cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pembrolizumab and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pembrolizumab and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pembrolizumab and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pembrolizumab and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/